September 14, 2026 · FDA / Psychedelic drugs / Therapeutic development / Public hearing
FDA holds public hearing on potential future therapeutic use of psychedelic drugs
The FDA held a September 14 public hearing with federal partners to gather input on the potential future therapeutic use of drug products containing psychedelic substances in supervised and supportive settings. Reuters described the hearing as part of a broader Trump-administration effort to accelerate development of psychedelic therapies for serious mental-health conditions. The hearing itself was an information-gathering proceeding: it did not approve a specific product, legalize psychedelic use, or change federal controlled-substance scheduling.
Open the full dated evidence record →